ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Sublingual Immunotherapy (SLIT) Quality of Life Outcomes

by Sue Pondrom • August 1, 2007

  • Tweet
  • Email
Print-Friendly Version
Sarah K. Wise, MD

You Might Also Like

  • Improving Quality of Life for Allergic and Nonallergic Rhinitis Patients
  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • FDA Approves First Sublingual Allergy Immunotherapy Agents
  • SLIT vs SCIT: A Q&A
Explore This Issue
August 2007
Sarah K. Wise, MD

SAN DIEGO-Sublingual immunotherapy (SLIT) is effective in controlling allergic symptoms in a preliminary patient cohort, according to a study presented April 27 at the Combined Otolaryngology Spring Meeting. Offered as part of the American Rhinologic Society program, the study looked at SLIT as an alternative to traditional subcutaneous immunotherapy (SCIT), which has resulted in several documented deaths and raised safety concerns.

Presenter Sarah K. Wise, MD, rhinology fellow and clinical instructor at the Medical University of South Carolina in Charleston, told the audience that SLIT is routinely performed in Europe but has not been as popular as SCIT in the United States, in spite of reports of a shorter escalation period, few cases of systemic reactions, and easy administration by patients at home. Although the World Health Organization and the European Academy of Allergology and Clinical Immunology concluded in 1998 that SLIT is a viable alternative to SCIT, it has not yet been approved by the US Food and Drug Administration.

Although worldwide studies have shown decreased allergy symptom scores, reduction in allergy medication use, improved quality of life, decreased bronchodilator use, decreased frequency of asthma exacerbations, and increased FEV1 and peak expiratory flow, US studies assessing the efficacy of SLIT are lacking, Dr. Wise said.

Structure of the Study

In the South Carolina study, patients with seasonal and perennial allergic rhinitis and/or allergic fungal sinusitis (five males and 10 females) with appropriate allergen reactivity on skin testing were given the option to pursue immunotherapy by traditional SCIT or by SLIT. Patients choosing SLIT completed the Mini-Rhinoconjunctivitis Quality of Life Questionnaire (mRQLQ), a 14-item forced-choice Likert-type questionnaire, at baseline and during SLIT maintenance therapy. Patients typically reached maintenance therapy in five weeks.

Dr. Wise said that maintenance mRQLQ showed statistically significant improvement in 12 of 14 domains, including impact on regular and recreational activities, sleep, nose rubbing and nose blowing, stuffy nose and runny nose, itchy eyes, sore eyes, watery eyes, thirst, and tiredness. Additionally, total RQLQ score showed statistically significant improvement (p = 0.001) as early as six weeks after initiation of therapy. Baseline total mRQLQ score of 27.8 decreased to 12.6 during maintenance. Maintenance mRQLQ was assessed at a mean of 2.9 months, with a range of five weeks to seven months.

Safety and Efficacy

One of the biggest arguments for SLIT is its safety profile, Dr. Wise told COSM participants, noting few reports of systemic reactions, as compared to SCIT systemic reaction rates of 0.5% to 5.6%. The typical side effects of SLIT, she said, are oral itching, stomachache, and nausea, with very rare withdrawal rates from SLIT studies for adverse reactions.

Pages: 1 2 | Single Page

Filed Under: Everyday Ethics, Head and Neck, Laryngology Issue: August 2007

You Might Also Like:

  • Improving Quality of Life for Allergic and Nonallergic Rhinitis Patients
  • Sublingual Immunotherapy a Potential Treatment for Allergic Rhinitis
  • FDA Approves First Sublingual Allergy Immunotherapy Agents
  • SLIT vs SCIT: A Q&A

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.